CN Patent

CN110117300A — 包含钠-葡萄糖协同转运蛋白1抑制剂的药物用途

Assigned to Chengdu Institute of Biology of CAS · Expires 2019-08-13 · 7y expired

What this patent protects

本发明涉及一种钠‑葡萄糖协同转运蛋白1(SGLT1)抑制剂包含它们组合物的药物合成方法以及它们在治疗代谢类疾病尤其是2型糖尿病的用途。

USPTO Abstract

本发明涉及一种钠‑葡萄糖协同转运蛋白1(SGLT1)抑制剂包含它们组合物的药物合成方法以及它们在治疗代谢类疾病尤其是2型糖尿病的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN110117300A
Jurisdiction
CN
Classification
—
Expires
2019-08-13
Drug substance claim
No
Drug product claim
No
Assignee
Chengdu Institute of Biology of CAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.